It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mislocalization of the predominantly nuclear RNA/DNA binding protein, TDP-43, occurs in motor neurons of ~95% of amyotrophic lateral sclerosis (ALS) patients, but the contribution of axonal TDP-43 to this neurodegenerative disease is unclear. Here, we show TDP-43 accumulation in intra-muscular nerves from ALS patients and in axons of human iPSC-derived motor neurons of ALS patient, as well as in motor neurons and neuromuscular junctions (NMJs) of a TDP-43 mislocalization mouse model. In axons, TDP-43 is hyper-phosphorylated and promotes G3BP1-positive ribonucleoprotein (RNP) condensate assembly, consequently inhibiting local protein synthesis in distal axons and NMJs. Specifically, the axonal and synaptic levels of nuclear-encoded mitochondrial proteins are reduced. Clearance of axonal TDP-43 or dissociation of G3BP1 condensates restored local translation and resolved TDP-43-derived toxicity in both axons and NMJs. These findings support an axonal gain of function of TDP-43 in ALS, which can be targeted for therapeutic development.
Here, the authors show in human iPSC-derived motor neurons from ALS patients and a TDP-43 mouse model that axonal TDP-43 forms G3BP1 positive RNP condensates, which sequester mRNA of nuclear encoded mitochondrial proteins and decrease local protein synthesis in motor neuron axons and neuromuscular junctions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
2 CECAD Research Center and Center for Molecular Medicine (CMMC), University of Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
3 Pathology Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel (GRID:grid.413795.d) (ISNI:0000 0001 2107 2845)
4 University of Oxford, Nuffield Department of Clinical Neurosciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
6 Institut de Génétique Moléculaire de Montpellier, Montpellier, France (GRID:grid.429192.5) (ISNI:0000 0004 0599 0285)
7 National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, USA (GRID:grid.416870.c) (ISNI:0000 0001 2177 357X)
8 Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Department of Neurology, Sheba Medical Center, Ramat Gan, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)